stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Free cash flow
argenex SE's free cash flow for fiscal 2025 was $573.5M, compared with −$151.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.4B. Over the past ten years it has ranged from −$966.6M (fiscal 2022) to $573.5M (fiscal 2025) — the current reading is the highest in ten years. Free cash flow has risen for 3 consecutive fiscal years. argenex SE ranks 5th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $573.5M | — |
| FY2024 | −$151.0M | — |
| FY2023 | −$464.1M | — |
| FY2022 | −$966.6M | — |
| FY2021 | −$728.2M | — |
| FY2020 | −$403.6M | — |
| FY2019 | $104.0M | — |
| FY2018 | −$64.4M | — |
| FY2017 | −$41.7M | — |
| FY2016 | $10.8M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $643.0M | 12.12% |
| Dec 2025 | $573.5M | 83.23% |
| Jun 2025 | $313.0M | — |
| Dec 2024 | −$151.0M | — |
| 16 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $3.6B |
| RPRX Royalty Pharma PLC compare | $3.0B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $1.4B |
| ARGX argenex SE | $1.4B |
| INCY Incyte Corporation compare | $679.9M |
| ROIV Roivant Sciences Ltd. compare | −$821.1M |
| MRNA Moderna, Inc. compare | −$1.2B |
| RVMD Revolution Medicines, Inc. compare | −$1.4B |
| GMAB Genmab A/S Sponsored ADR compare | −$6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement